Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma. - Wikidata - awgldk - TriplyDB

Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.

Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.

http://www.wikidata.org/entity/Q37934952

about

Advancement in high dose therapy and autologous stem cell rescue in lymphoma Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma.

P2860

Q26795538-2DD35F8E-C472-4DB5-A10E-62AE00BF0BD8 Q33886267-AEF1C2C6-C580-4756-A60A-B7B0B6E0BA9F Q38099028-70ACB496-2097-48A9-A3DB-623419743161

P2860

Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.

http://www.wikidata.org/entity/Q37934952

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Double high-dose therapy with ...... d/refractory Hodgkin lymphoma.

@en

Double high-dose therapy with ...... d/refractory Hodgkin lymphoma.

@nl

type

label

Double high-dose therapy with ...... d/refractory Hodgkin lymphoma.

@en

Double high-dose therapy with ...... d/refractory Hodgkin lymphoma.

@nl

prefLabel

Double high-dose therapy with ...... d/refractory Hodgkin lymphoma.

@en

Double high-dose therapy with ...... d/refractory Hodgkin lymphoma.

@nl

P1433

Q37934952-16EB6571-95F2-49F8-8A65-D05F39F2208C

P1476

Q37934952-E59F8A4F-8F88-4F40-B679-FF67AA7042B7

P2093

Q37934952-11F2699D-B07F-4271-B0E0-7F2BC374C95E

Q37934952-6439F281-F04F-4395-A6FF-3410DCE67D78

Q37934952-6E5AF75E-7D30-461E-B60F-108986E602EA

Q37934952-9A189703-9FDD-450E-A8DE-121D3E08DD1D

Q37934952-AC8C5175-82B8-4F97-B94B-6CCED3F5920C

Q37934952-E329553E-F38A-4920-ABE6-5CF01D9D77F7

P2860

Q37934952-13E7AB30-C42B-4F03-B523-8DA201B27DB9

Q37934952-1ABF8536-10F9-4A34-B631-E9DDF1AD7E51

Q37934952-1D9C6D76-4D2A-44C1-8363-F60195E83A44

Q37934952-1F47094B-77B2-4174-9160-175E72F4CFE6

Q37934952-290F14AB-FD47-4EAE-B576-6610971E646A

Q37934952-3CE52F7E-A94F-4B32-BF1A-33E89A37FBFF

Q37934952-4AD46692-263C-4F63-81E5-599024543424

Q37934952-4C58F638-7A0F-430A-AEE4-CF00B851F024

Q37934952-53240C6D-6577-4E70-B431-680A36DA8F03

Q37934952-53E958D2-B2FD-4FD0-9FF6-1A1ECE1BCE92

P304

Q37934952-F56366F1-99B5-48C3-A8D1-A8FF19651322

P31

Q37934952-63EAF0E6-F3BE-4709-B62E-C11E089B79AA

P356

Q37934952-D6ABEFB1-E991-4728-9163-37778348418C

P433

Q37934952-4600EC63-A112-4169-A6C7-F55C005B94BD

P478

Q37934952-7380D0E8-825F-48A7-A0ED-623134AE29E4

P577

Q37934952-92B40012-3AD9-4DF0-9861-AC313336F7E8

P698

Q37934952-20D730DA-7E81-474A-ACEC-293AB5AF4962

P356

10428194.2011.624227

P1433

Leukemia & Lymphoma

P1476

Double high-dose therapy with ...... d/refractory Hodgkin lymphoma.

@en

P2093

Alex Balogh

http://www.w3.org/2001/XMLSchema#string

Douglas A Stewart

http://www.w3.org/2001/XMLSchema#string

James Russell

http://www.w3.org/2001/XMLSchema#string

Mona Shafey

http://www.w3.org/2001/XMLSchema#string

Peter Duggan

http://www.w3.org/2001/XMLSchema#string

Qiuli Duan

http://www.w3.org/2001/XMLSchema#string

P2860

Standard therapy of advanced Hodgkin lymphoma

Nonparametric Estimation from Incomplete Observations

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

P304

596-602

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2011.624227

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21929284

http://www.w3.org/2001/XMLSchema#string